Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several key claims are not supported by the provided FDA label excerpts, including specific black-box warning attributions, quantitative risks (e.g., suicidal thoughts 5%, injection-site reactions up to 85%), and specific monitoring frequency. Multiple statements are inconsistent with the provided label (e.g., pregnancy risk framing and discontinuation/monitoring details).
Category Scores
Accurate Statements
Betaseron (interferon beta-1b) is used for relapsing forms of multiple sclerosis.
Section 1: “BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.”
Betaseron has subcutaneous dosing (every other day) with a recommended starting dose of 0.0625 mg and titration to 0.25 mg every other day over six weeks.
Section 2.1: “The recommended starting dose is 0.0625 mg… subcutaneously every other day, with dose increases over a six-week period to… 0.25 mg… every other day.”
Concurrent use of analgesics and/or antipyretics on treatment days may help ameliorate flu-like symptoms associated with Betaseron.
Section 2.4: “Concurrent use of analgesics and/or antipyretics on treatment days may help ameliorate flu-like symptoms associated with BETASERON use.”
Injection site reactions including injection site necrosis can occur with interferon beta products including Betaseron.
Section 5.5: “Injection site reactions, including injection site necrosis, can occur with the use of interferon beta products, including BETASERON.”
Injection site necrosis was reported in 4% of Betaseron-treated patients in controlled clinical trials (0% on placebo).
Section 5.5: “Injection site necrosis (ISN) was reported in 4% of BETASERON-treated patients… compared to 0% on placebo.”
Betaseron is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, Albumin (Human), or any other component.
Section 4: “BETASERON is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, Albumin (Human), or any other component of the formulation.”
Flu-like symptom complex occurred in 57% of patients on Betaseron in controlled clinical trials.
Section 5.9: “the rate of flu-like symptom complex for patients on BETASERON was 57%”
Baseline clinical study reports include flu-like symptoms and myalgia among commonly reported adverse reactions.
Section 6.1: “the most commonly reported adverse reactions … injection site reaction, lymphopenia, flu-like symptoms, myalgia, leukopenia, neutropenia, increased liver enzymes…”
Rotate injection sites to minimize the likelihood of severe injection site reactions including necrosis or localized infection.
Section 2.3: “rotate sites for subcutaneous injections to minimize the likelihood of severe injection site reactions, including necrosis…”
Unsupported Statements
Betaseron causes flu-like symptoms in most patients, including fever, chills, fatigue, muscle aches, and sweating.
The provided label excerpts state the rate of “flu-like symptom complex” was 57% (Section 5.9) but do not enumerate fever/chills/fatigue/sweating as included components or imply “most patients.”
Flu-like symptoms often improve over time with dose titration or pain relievers like acetaminophen.
The excerpts only state analgesics/antipyretics may help ameliorate symptoms on treatment days (Section 2.4); no claim about improvement over time, dose titration effect, or acetaminophen specifically is supported.
Injection-site reactions occur frequently with Betaseron.
Although injection site reactions are common (Section 6.1 lists them among most commonly reported adverse reactions), the provided excerpts do not support the specific “frequently” phrasing as a quantitative rate.
Betaseron injection-site reactions include redness, swelling, pain, or necrosis.
The excerpt confirms injection site reactions including necrosis (Section 5.5) but does not list redness/swelling/pain as specific labeled components.
Betaseron injection-site reactions (redness, swelling, pain, or necrosis) occur in up to 85% of users.
The provided excerpts include “Injection site reaction… 78%” (Section 6.1). There is no label support for “up to 85%.”
Betaseron has black-box warnings for liver damage.
The provided label excerpts do not mention black-box warnings, and no liver black-box warning text is supplied.
Betaseron can cause elevated liver enzymes.
While “increased liver enzymes” is listed among common adverse reactions (Section 6.1), the broader wording about severity is not unsupported; however this statement itself is partially supported by the excerpt. Included here only if interpreted as a distinct claim beyond the excerpted phrase; the provided label supports the concept “increased liver enzymes.”
Patients receiving Betaseron should have liver enzymes monitored monthly.
No monitoring schedule (monthly) for liver enzymes is present in the provided excerpts.
Betaseron can cause rare cases of liver failure.
The provided excerpts mention “increased liver enzymes” but do not support “liver failure” or rarity.
Betaseron has black-box warnings for blood disorders.
No black-box warning text for blood disorders is present in the provided excerpts.
Betaseron can cause low white blood cells (neutropenia).
“neutropenia” is listed among commonly reported adverse reactions (Section 6.1), so this specific claim is supported in substance, but no explicit phrasing “low white blood cells (neutropenia)” is provided verbatim.
Betaseron can cause low platelets (thrombocytopenia).
Thrombocytopenia is not mentioned in the provided excerpts.
Betaseron-associated neutropenia increases infection risk.
The provided excerpts do not state increased infection risk from neutropenia.
Betaseron-associated thrombocytopenia increases bleeding risk.
The provided excerpts do not mention thrombocytopenia or bleeding risk.
Betaseron has black-box warnings for heart issues.
No black-box warning text for heart issues is present in the provided excerpts.
Betaseron can rarely cause cardiomyopathy.
Cardiomyopathy is not mentioned in the provided excerpts.
Betaseron can rarely cause heart failure.
Heart failure is not mentioned in the provided excerpts.
Betaseron should be avoided in severe cardiac disease.
No statement about avoiding severe cardiac disease is present in the provided excerpts (PAH is mentioned, but not “severe cardiac disease” generally).
Betaseron has black-box warnings for mental health effects.
No black-box warning text for mental health effects is present in the provided excerpts.
Betaseron can cause depression.
Depression is not mentioned in the provided excerpts.
Betaseron can cause suicidal thoughts.
Suicidal thoughts are not mentioned in the provided excerpts.
The risk of suicidal thoughts with Betaseron is 5%.
No such numeric risk is present in the provided excerpts.
Patients should be screened carefully for mental health effects when using Betaseron.
No mental health screening guidance is present in the provided excerpts.
Betaseron has black-box warnings for allergic reactions.
No black-box warning text for allergic reactions is present in the provided excerpts.
Anaphylaxis is possible with Betaseron.
No anaphylaxis statement is present in the provided excerpts.
Long-term use of Betaseron is linked to thyroid dysfunction.
Thyroid dysfunction is not mentioned in the provided excerpts.
Long-term use of Betaseron is associated with rare seizures.
Seizures are not mentioned in the provided excerpts.
Use of Betaseron in pregnancy is associated with potential fetal harm (Category C).
The pregnancy excerpt states available data have not generally indicated a drug-associated risk of major birth defects, and does not describe an FDA pregnancy category “C.”
Betaseron should be used with caution in patients with depression history.
No depression history caution is present in the provided excerpts.
Betaseron should be used with caution in patients with liver disease.
No liver disease caution is present in the provided excerpts.
Betaseron should be used with caution in patients with seizure disorders.
No seizure disorder caution is present in the provided excerpts.
Betaseron has not been studied in children under 18.
No pediatric study statement is present in the provided excerpts.
Baseline blood tests (CBC and liver enzymes) are required before starting Betaseron.
No requirement for CBC is present in the provided excerpts.
Monthly checks of blood tests are recommended for the first 6 months of Betaseron treatment.
No monitoring schedule is present in the provided excerpts.
Betaseron dosing should be started at half dose (0.0625 mg).
Starting dose 0.0625 mg is supported (Section 2.1), but the phrase “half dose” is not supported by the excerpt.
Betaseron should be titrated to 0.25 mg every other day.
Titration to the recommended dose 0.25 mg every other day over six weeks is supported; included only if interpreted as “titrated” without the six-week period detail.
Premedication with ibuprofen or acetaminophen is recommended to manage side effects when starting Betaseron.
The excerpt supports “analgesics and/or antipyretics” may help (Section 2.4) but does not name ibuprofen or acetaminophen nor say “recommended to manage… when starting.”
Betaseron reduces MS relapses by 30%.
The provided clinical study excerpt does not include the specific 30% relapse reduction figure.
Betaseron reduces MRI lesions.
The excerpt states a “lower number of newly active lesions” (Section 14), which supports lesion reduction; however the exact statement “reduces MRI lesions” is not explicitly tied to MRI in the provided excerpt.
15% to 20% of patients discontinue Betaseron due to side effects.
No discontinuation rate is provided in the excerpts.
There is no evidence of increased mortality with Betaseron.
No mortality statement is present in the provided excerpts.
Contradictions
Low
AI Statement
Use of Betaseron in pregnancy is associated with potential fetal harm (Category C).
Label Reference
Section 8.1: “available data… have not generally indicated a drug-associated risk of major birth defects with interferon beta-1b during pregnancy.” (No “Category C” labeling in excerpt.)
Low
AI Statement
Betaseron injection-site reactions (redness, swelling, pain, or necrosis) occur in up to 85% of users.
Label Reference
Section 6.1: “Injection site reaction… 78%”
Low
AI Statement
Betaseron causes flu-like symptoms in most patients...
Label Reference
Section 5.9: flu-like symptom complex rate 57%
Important Omissions
Denial/absence of support for unspecified black-box warnings: the AI response repeatedly asserts black-box warnings for multiple domains (liver, blood disorders, heart issues, mental health effects, allergic reactions), but the provided label excerpts do not contain any black-box warning statements.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Multiple quantitative and categorical safety claims (e.g., black-box warning presence, suicidal thoughts risk %, injection-site reaction rates up to 85%, liver enzyme monitoring frequency) are not supported by the provided label excerpts. These inaccuracies could mislead clinicians/patients about risk magnitude and monitoring intensity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large number of claims are unsupported by the supplied label excerpts, including black-box warning assertions and multiple numeric risk/monitoring statements; several conflict with label-provided rates (e.g., injection site reaction 78% vs claimed up to 85%).
Suggested Improvement
Restrict statements to what is explicitly supported by the provided label excerpts (e.g., flu-like symptom complex rate 57%, injection site reaction 78%, injection site necrosis 4%, starting dose/titration schedule, and the documented hypersensitivity contraindication). Remove black-box warning claims and unsupported numeric risks/monitoring schedules or provide matching label text if available.